Overall Survival of Large Cell Neuroendocrine Lung Cancer Patients - a Retrospective Study

This is a retrospective study. 132 patients with LCNEC and combined LCNEC were included to the analysis. Patients were treated with radical, palliative or symptomatic intension between 2002-2018 in central and north-eastern centres in Poland. The group of patients consists of 47 women (36%) and 85 men (64%). Ratio of women to men is 1:1,81. The observation period ranged from 0 to 192 months.

For all patients included to the analysis, the clinical stage was estimated according to TNM Classification of Malignant Tumours - UICC from 2017. The degree of pathomorphic stage (pTNM) was assessed in 60 patients treated with intention to treat (ITT), which is 45% of the total population.

The degree of clinical stage (cTNM) was assessed in 72 patients based on the imaging examinations (including PET, CT, MRI, bone scintigraphy, etc.) and fine needle aspiration biopsy (FNA) (including EBUS, with pathological confirmation of LCNEC, which is 55% of the total population.

The clinical stage (cTNM) was used in case of patients disqualified from radical surgery due to: advanced disease, contraindications to surgery, no patient's consent for treatment.

Inclusion criteria

• Adults ≥18 years old, male or female, with pathologically confirmed primary neuroendocrine lung cancer based on histopathological examination:

• LCNEC
• combined type LCNEC
• Patients with LCNEC, combined LCNEC without prior treatment independently from the clinical stage according to the 8th edition of TNM 2017
• Patients with generalized, unresectable of LCNEC, combined LCNEC before, during and after palliative treatment
• Patients with generalized, unresectable LCNEC, combined LCNEC treated only symptomatically
• Patients with locally advanced, unresectable LCNEC,combined LCNEC before, during and after radical treatment
• Patients with locally advanced, resectable LCNEC, combined LCNEC before, during and after treatment

Exclusion criteria

• NA